Leeza Osipenko

536 total citations
22 papers, 317 citations indexed

About

Leeza Osipenko is a scholar working on Economics and Econometrics, Public Health, Environmental and Occupational Health and Physiology. According to data from OpenAlex, Leeza Osipenko has authored 22 papers receiving a total of 317 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Economics and Econometrics, 3 papers in Public Health, Environmental and Occupational Health and 3 papers in Physiology. Recurrent topics in Leeza Osipenko's work include Health Systems, Economic Evaluations, Quality of Life (11 papers), Pharmaceutical Economics and Policy (9 papers) and Biomedical Ethics and Regulation (3 papers). Leeza Osipenko is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (11 papers), Pharmaceutical Economics and Policy (9 papers) and Biomedical Ethics and Regulation (3 papers). Leeza Osipenko collaborates with scholars based in United Kingdom, United States and Denmark. Leeza Osipenko's co-authors include Alexander Poletaev, Elías Mossialos, Huseyin Naci, John A. Hickman, Jack W. Scannell, Deborah Morrison, Michael Anderson, Kevin Marsh, Tracey Jones-Hughes and Chris Cooper and has published in prestigious journals such as Nature Reviews Drug Discovery, BMJ and Journal of Clinical Epidemiology.

In The Last Decade

Leeza Osipenko

20 papers receiving 307 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Leeza Osipenko United Kingdom 9 115 46 46 42 36 22 317
R. Babela Slovakia 6 77 0.7× 29 0.6× 16 0.3× 22 0.5× 78 2.2× 23 452
Rachel Archer United Kingdom 11 86 0.7× 31 0.7× 54 1.2× 87 2.1× 30 0.8× 22 467
Grace Hampson United Kingdom 9 187 1.6× 23 0.5× 16 0.3× 41 1.0× 53 1.5× 23 366
Laura Longo Italy 10 94 0.8× 17 0.4× 49 1.1× 31 0.7× 44 1.2× 27 377
Enrico Costa Italy 8 91 0.8× 51 1.1× 31 0.7× 27 0.6× 39 1.1× 26 284
Alice Bessey United Kingdom 9 18 0.2× 39 0.8× 22 0.5× 77 1.8× 34 0.9× 12 327
Ashwini Shewade United States 9 36 0.3× 57 1.2× 45 1.0× 49 1.2× 14 0.4× 25 266
Claudia Ching Yan Chung Hong Kong 12 73 0.6× 31 0.7× 6 0.1× 33 0.8× 104 2.9× 30 487
Sean P. Gavan United Kingdom 7 66 0.6× 10 0.2× 8 0.2× 25 0.6× 30 0.8× 30 232
Nicholas Adlard Switzerland 13 111 1.0× 5 0.1× 58 1.3× 47 1.1× 30 0.8× 46 524

Countries citing papers authored by Leeza Osipenko

Since Specialization
Citations

This map shows the geographic impact of Leeza Osipenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leeza Osipenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leeza Osipenko more than expected).

Fields of papers citing papers by Leeza Osipenko

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leeza Osipenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leeza Osipenko. The network helps show where Leeza Osipenko may publish in the future.

Co-authorship network of co-authors of Leeza Osipenko

This figure shows the co-authorship network connecting the top 25 collaborators of Leeza Osipenko. A scholar is included among the top collaborators of Leeza Osipenko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leeza Osipenko. Leeza Osipenko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Osipenko, Leeza, et al.. (2024). Assessment of quality of data submitted for NICE technology appraisals over two decades. BMJ Open. 14(2). e074341–e074341.
2.
Osipenko, Leeza, et al.. (2023). The Origin of First‐in‐Class Drugs: Innovation Versus Clinical Benefit. Clinical Pharmacology & Therapeutics. 115(2). 342–348. 4 indexed citations
3.
Osipenko, Leeza, et al.. (2023). Costs and Causes of Oncology Drug Attrition With the Example of Insulin-Like Growth Factor-1 Receptor Inhibitors. JAMA Network Open. 6(7). e2324977–e2324977. 22 indexed citations
4.
Osipenko, Leeza, et al.. (2023). Provenance and Clinical Benefit of Medicines Introduced to the French Market, 2008 to 2018. JAMA Internal Medicine. 184(1). 46–46.
5.
Nowrouzi‐Kia, Behdin, et al.. (2022). The early impact of the global lockdown on post-secondary students and staff: A global, descriptive study. SAGE Open Medicine. 10. 3911925296–3911925296. 11 indexed citations
6.
Osipenko, Leeza. (2021). Audit of data redaction practices in NICE technology appraisals from 1999 to 2019. BMJ Open. 11(10). e051812–e051812. 7 indexed citations
7.
Naci, Huseyin, et al.. (2020). NICE's evaluations of medicines authorized by EMA with conditional marketing authorization or under exceptional circumstances. International Journal of Technology Assessment in Health Care. 36(4). 426–433. 9 indexed citations
8.
Hopkin, Gareth, et al.. (2020). Assessment of technical errors and validation processes in economic models submitted by the company for NICE technology appraisals. International Journal of Technology Assessment in Health Care. 36(4). 311–316. 6 indexed citations
9.
Osipenko, Leeza. (2019). Blockchain’s potential to improve clinical trials—an essay by Leeza Osipenko. BMJ. 367. l5561–l5561. 4 indexed citations
10.
Anderson, Michael, Huseyin Naci, Deborah Morrison, Leeza Osipenko, & Elías Mossialos. (2018). A review of NICE appraisals of pharmaceuticals 2000–2016 found variation in establishing comparative clinical effectiveness. Journal of Clinical Epidemiology. 105. 50–59. 30 indexed citations
11.
Ambrose, Susan A., Huseyin Naci, C. G. C. CHESTERS, Leeza Osipenko, & Elías Mossialos. (2018). PHP289 - AN EXAMINATION OF DELAYS DURING NICE TECHNOLOGY APPRAISAL REVIEWS. Value in Health. 21. S199–S199. 1 indexed citations
12.
Naci, Huseyin, et al.. (2018). Assessment of Devices, Diagnostics and Digital Technologies: A Review of NICE Medical Technologies Guidance. Applied Health Economics and Health Policy. 17(2). 189–211. 10 indexed citations
13.
Maignen, F., et al.. (2017). Outcomes of early health technology assessment dialogues in medicinal product development. Nature Reviews Drug Discovery. 16(2). 79–79. 2 indexed citations
14.
Osipenko, Leeza, et al.. (2017). National telemedicine and telehealth policy context in England and introduction of digital innovations for detection and treatment of sexually transmitted infections. Oxford University Research Archive (ORA) (University of Oxford). 3(1). 1 indexed citations
15.
Maignen, F., et al.. (2016). Integrating health technology assessment requirements in the clinical development of medicines: the experience from NICE scientific advice. European Journal of Clinical Pharmacology. 73(3). 297–305. 6 indexed citations
16.
Maignen, F., et al.. (2014). Trends In Early Engagement Between Industry And HTA: Analysis of Scientific Advice Service Provided By Nice Since 2009. Value in Health. 17(7). A441–A441. 5 indexed citations
17.
Cherry, Mary Gemma, J Greenhalgh, Leeza Osipenko, et al.. (2012). The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.. Health Technology Assessment. 16(43). 1–129. 34 indexed citations
18.
Cherry, Mary Gemma, et al.. (2012). Flow diagram of included studies. 1 indexed citations
19.
Pavey, Toby, Martin Hoyle, Oriana Ciani, et al.. (2012). Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.. Health Technology Assessment. 16(42). iii–iv, 1. 44 indexed citations
20.
Poletaev, Alexander & Leeza Osipenko. (2003). General network of natural autoantibodies as immunological homunculus (Immunculus). Autoimmunity Reviews. 2(5). 264–271. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R. Babela Breakdown of academic impact, for papers by Rachel Archer Breakdown of academic impact, for papers by Grace Hampson Breakdown of academic impact, for papers by Laura Longo Breakdown of academic impact, for papers by Enrico Costa Breakdown of academic impact, for papers by Alice Bessey Breakdown of academic impact, for papers by Ashwini Shewade Breakdown of academic impact, for papers by Claudia Ching Yan Chung Breakdown of academic impact, for papers by Sean P. Gavan Breakdown of academic impact, for papers by Nicholas Adlard
Rankless by CCL
2026